

1            Selective Oxidation of Pharmaceuticals and  
2            Suppression of Perchlorate Formation during  
3            Electrolysis of Fresh Human Urine

4            *James A. Clark,<sup>†</sup> Yuhang Yang,<sup>‡</sup> Nathanael C. Ramos,<sup>†</sup> Michael C. Dodd,<sup>§</sup> and*

5            *Hugh W. Hillhouse<sup>†,\*</sup>*

6            <sup>†</sup> Department of Chemical Engineering, Clean Energy Institute, Molecular Engineering &  
7            Sciences Institute, University of Washington, Seattle, Washington 98195-1750


8            <sup>‡</sup> Department of Materials Science and Engineering, University of Washington, Seattle,  
9            Washington 98195-2120

10           <sup>§</sup> Department of Civil & Environmental Engineering, University of Washington, Seattle,  
11           Washington 98195-2700

12           \* Email: h2@uw.edu

13 **Abstract**

14 Many pharmaceutical compounds are excreted unchanged or as active metabolites via urine.  
15 They pass through conventional wastewater treatment processes, and present a risk to aquatic  
16 ecosystems and humans. Point-source remediation of source-separated urine provides a promising  
17 alternative to destroy pharmaceuticals before dilution with wastewater. Electrochemical advanced  
18 oxidation processes are one possible option for degrading pharmaceuticals in urine, but they often  
19 lead to the formation of oxidation byproducts (OBPs) including chlorate, perchlorate, and  
20 halogenated organics at hazardous concentrations due to high background chloride concentrations.  
21 Here, we show that the high urea content of fresh human urine suppresses the formation of  
22 oxychlorides by inhibiting formation of HOCl/OCl<sup>-</sup> during electrolysis, while still enabling the  
23 oxidation of pharmaceuticals by <sup>•</sup>OH due to the slow rate of urea oxidation by <sup>•</sup>OH. This results in  
24 improved performance when compared to equivalent treatment of hydrolyzed aged urine. This  
25 (primarily indirect) electrochemical oxidation scheme is shown to degrade the model  
26 pharmaceuticals cyclophosphamide and sulfamethoxazole with surface-area-to-volume-  
27 normalized pseudo-first-order observed rate constants greater than 0.08 cm/min in authentic fresh  
28 human urine matrixes. It results in two orders-of-magnitude decrease in pharmaceutical  
29 concentrations in 2 hours while generating three orders-of-magnitude lower oxychloride byproduct  
30 concentrations in synthetic fresh urine as compared to synthetic hydrolyzed aged urine matrixes.  
31 Importantly, this proof-of-principle shows that simple and safe electrochemical methods can be  
32 used for point-source-remediation of pharmaceuticals in fresh human urine (before storage and  
33 hydrolysis), without formation of significant oxychloride byproducts.



34

35 **TOC Figure.** (no caption)

36

## 37 **1. Introduction**

38 Many pharmaceutical compounds are not sufficiently deactivated during typical wastewater  
 39 treatment and eventually end up being discharged into the environment. These pharmaceuticals  
 40 may threaten aquatic ecosystems,<sup>1</sup> contribute to the development of antibiotic-resistant bacteria,<sup>2</sup>  
 41 and can eventually return to human drinking water supplies.<sup>3</sup> Chemical oxidation and advanced  
 42 oxidation processes (AOPs) are an important means of addressing this growing problem because  
 43 of their ability to degrade organic contaminants via oxidizing species (i.e.,  $\bullet\text{OH}$ ,  $\text{O}_3$ , etc., in  
 44 addition to  $\text{HOCl}$ ,  $\text{Cl}^\bullet$ , and  $\text{Cl}_2^{\bullet-}$  in free chlorine or chloride containing solutions) through chemical,  
 45 photochemical, or electrochemical means.<sup>4-6</sup> Numerous studies have examined pharmaceutical  
 46 degradation using AOPs,<sup>7-13</sup> and there are many proposed strategies ranging from large-scale  
 47 implementation as a tertiary treatment step at centralized wastewater treatment facilities (WWTFs)  
 48 to small-scale decentralized implementation to treat point sources.


49 Point-source treatment for pharmaceutical pollutants at homes, businesses, and hospitals is  
 50 attractive because the compounds may be treated before they are diluted by a factor of 1,000 with  
 51 other wastewater. However, strategies that employ the addition of chemical agents<sup>14</sup> (Fenton's

52 reagent, peroxides or other oxidants or catalysts) are unsuitable for distributed or in-home use due  
53 to safety concerns regarding the handling of oxidants, removal or disposal of wastes from the  
54 process, and high-cost. This study focuses on the underlying chemistry relevant to application of  
55 electrochemical advanced oxidation processes (EAOPs) for treatment of fresh urine. These EAOPs  
56 have the potential to enable point-source approaches to treatment of fresh urine that are safe and  
57 easy to operate since they do not require the addition of oxidants or generate new waste streams.  
58 The two biggest challenges facing this approach are the relatively low concentrations of  
59 pharmaceuticals and the potential formation of oxidation byproducts (OBPs) that can result from  
60 oxidation of co-occurring chloride and other halides. Many studies highlight that OBPs formed  
61 during AOPs can create serious environmental and human health problems on their own,<sup>15</sup>  
62 including chlorate, perchlorate, haloacetic acids, aliphatic halide species, haloacetonitriles,  
63 haloacetamides, and nitrosamines. The halogenated OBPs are mostly chlorinated species;  
64 however, brominated and iodinated species may be present at much lower concentrations but with  
65 higher toxicity.<sup>16</sup> Thus, there is a need to develop novel EAOPs or improved approaches to  
66 employing existing EAOPs that enable high efficiency toward pharmaceutical destruction while  
67 preventing or mitigating OBP formation.

68 The dominant route for the elimination of non-volatile pharmaceutical excretion is via urine.<sup>17-</sup>

69 <sup>19</sup> Of the top 200 prescribed drugs in the U.S., roughly 30% of the ingested pharmaceutical load is  
70 excreted unchanged via urine, while ~65% is metabolized and excreted via both urine and feces  
71 with the remaining ~5% via biliary elimination.<sup>20</sup> Further, some metabolites retain key  
72 pharmacological properties of parent compounds, and many of them will remain active.<sup>21</sup> Thus,  
73 targeting treatment of urine (before dilution) is an attractive strategy to reduce pharmaceutical  
74 pollution. While the high electrical conductivity of urine (due primarily to chloride salts) is an

75 advantage for EAOPs, the presence of high concentrations of urea or ammonium (over two orders  
 76 of magnitude greater than pharmaceutical concentrations) could be a major hurdle forcing one to  
 77 oxidize most of the urea before significant oxidation of the pharmaceuticals. In this study, we show  
 78 that the unusually slow rate of urea oxidation by the hydroxyl radical ( $\cdot\text{OH}$ ) ( $7.9 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$  for  
 79 urea<sup>22</sup> vs.  $2 \times 10^9 \text{ M}^{-1}\text{s}^{-1}$  for cyclophosphamide<sup>23</sup> and  $6.2 \times 10^9 \text{ M}^{-1}\text{s}^{-1}$  for sulfamethoxazole<sup>24</sup>)  
 80 provides a de facto selectivity for  $\cdot\text{OH}$  attack on the other organics (**Scheme 1**,  $r_1$  and  $r_3$ ).




81

82 **Scheme 1.** Relative rate constants for important reactions during the electrolysis of  
 83 pharmaceuticals in urine matrixes (with cyclophosphamide as an example pharmaceutical in an  
 84 undivided cell setup). The formation of chlorate ( $\text{ClO}_3^-$ ) and perchlorate ( $\text{ClO}_4^-$ ) can be suppressed  
 85 by the presence of high nitrogen concentration (i.e., urea or  $\text{NH}_4^+/\text{NH}_3$ ). Divided cell architectures  
 86 will block  $r_{21}$  and subsequent reactions. The relative rates of these reactions are important to

87 consider to successfully decrease pharmaceutical concentrations while not generating OBPs. The  
88 color coding indicates the relative range of large to small rate constants. It is noteworthy that  
89 reactions  $r_{11-14}$  involving urea and  $\text{NH}_4^+/\text{NH}_3$  as reactants with high concentration will have high  
90 reaction rates, even though the second-order rate constants for these reactions are lower relative to  
91 other depicted reactions. The black arrows represent the transport of species. Furthermore,  $\bullet\text{OH}$ ,  
92  $\text{Cl}\bullet$  and  $\text{Cl}_2^{\bullet-}$  depicted at the anode surface may also desorb and diffuse outward through a  
93 relatively stagnant near-anode region. Likewise,  $\text{Cl}^-$ , urea, and the pharmaceuticals diffuse from  
94 bulk solution toward the anode as they are consumed at the anode or in the near-anode stagnant  
95 region. See Section 3.3 for discussion of the importance of mass transport in galvanostatic  
96 experiments.

97 Several studies have examined the application of EAOPs to various urine matrixes and have  
98 shown differences in the generation of OBPs. Studies have examined electrochemical treatment of  
99 synthetic urine<sup>25-31</sup> and human-generated stored urine,<sup>16, 32-35</sup> for multiple purposes including  
100 pharmaceutical degradation, distributed wastewater treatment, and nutrient recovery (for nitrogen  
101 and phosphorus). Interestingly, the concentrations of the OBPs reported for roughly equivalent  
102 oxidation treatments are vastly different. For example, many studies report large amounts (>10  
103 mM) of generated  $\text{ClO}_4^-$  after 30 A·hr/L of treatment using a boron-doped diamond (BDD)  
104 electrode,<sup>16, 29, 30, 35</sup> while a similar report measured  $\text{ClO}_4^-$  below the detection limit for the same  
105 normalized charge passed.<sup>31</sup> One critical difference between these studies that may explain these  
106 differences is the composition of the matrix. Fresh urine (authentic and synthetic) has a high  
107 concentration of urea – averaging 15 g/L (250 mM),<sup>36</sup> and a pH of about 6. By contrast, stored  
108 hydrolyzed authentic urine has a urea concentration of ~0 mM, ammonium concentration of 30-  
109 120 mM, bicarbonate/carbonate concentration of 25-30 mM, and a pH of about 9.<sup>32</sup> This is due to  
110 naturally abundant bacterial urease which hydrolyzes urea to form ammonium, bicarbonate, and  
111 hydroxide (eq 1).



113 This reaction happens rapidly, with one study finding that urea is nearly completely hydrolyzed  
114 within 5 hours of storage in a pipe.<sup>37</sup> The concentration of ammonium decreases over time with

115 elevation of pH and volatilization of ammonia if the solution is open to the atmosphere. The  
116 concentrations of carbonate species also decrease due to precipitation as CaCO<sub>3</sub>.<sup>38, 39</sup>

117 The hydrolysis of urea to NH<sub>4</sub><sup>+</sup> and HCO<sub>3</sub><sup>-</sup>, along with the volatilization of NH<sub>3</sub> and  
118 precipitation of CO<sub>3</sub><sup>2-</sup>, can have major impacts on the oxidation pathways during the application  
119 of an EAOP. One of the strongest oxidants produced in an EAOP is <sup>•</sup>OH (E<sup>0</sup> (<sup>•</sup>OH, H<sup>+</sup>/H<sub>2</sub>O) =  
120 2.32 V at pH 7),<sup>40</sup> which reacts rapidly with most organic molecules by either addition or hydrogen  
121 abstraction (**Scheme 1**, r<sub>3</sub>), with second-order rate constants typically in the range of 10<sup>9</sup> ~ 10<sup>10</sup> M<sup>-1</sup>  
122 s<sup>-1</sup>.<sup>22</sup> However, this important radical is scavenged by NH<sub>3</sub> and HCO<sub>3</sub><sup>-</sup>/CO<sub>3</sub><sup>2-</sup> in hydrolyzed urine  
123 much faster than by the urea in fresh urine (eqs. 2-5), with respective pseudo-first-order scavenging  
124 rate constants, k' = 2.6 × 10<sup>7</sup> s<sup>-1</sup> and 2.0 × 10<sup>5</sup> s<sup>-1</sup> (**Text S1**):<sup>22, 41</sup>



129 While the amino radical (E<sup>0</sup> (<sup>•</sup>NH<sub>2</sub>/NH<sub>3</sub>) = 0.6 V)<sup>42</sup> and carbonate radical (E<sup>0</sup> (CO<sub>3</sub><sup>•-</sup>/CO<sub>3</sub><sup>2-</sup>) =  
130 1.57 V)<sup>40</sup>, resulting from reactions of <sup>•</sup>OH with NH<sub>3</sub> and HCO<sub>3</sub><sup>-</sup>/CO<sub>3</sub><sup>2-</sup>, may also provide some  
131 oxidizing power, their second-order rate constants with most organic molecules are more than 3  
132 orders of magnitude smaller than <sup>•</sup>OH.<sup>42-45</sup> Further, <sup>•</sup>NH<sub>2</sub> will be rapidly scavenged by dissolved  
133 O<sub>2</sub> (**Scheme 1**, r<sub>19</sub>).<sup>41</sup> In urine matrixes with high chloride concentrations (~100 mM), reaction of  
134 <sup>•</sup>OH with Cl<sup>-</sup> (**Scheme 1**, r<sub>6</sub>) and direct anodic electron transfer from Cl<sup>-</sup> (**Scheme 1**, r<sub>5</sub>) will also  
135 lead to formation of the chlorine radicals, Cl<sup>•</sup> (E<sup>0</sup> (Cl<sup>•</sup>/Cl<sup>-</sup>) = 2.43 V)<sup>40</sup> and Cl<sub>2</sub><sup>•-</sup> (E<sup>0</sup> (Cl<sub>2</sub><sup>•-</sup>/Cl<sup>-</sup>) =  
136 2.13 V)<sup>40</sup>. They may also contribute to degradation of organic molecules (**Scheme 1**, r<sub>4</sub>), with rate  
137 constants for Cl<sup>•</sup> typically spanning a similar range as for <sup>•</sup>OH, and rate constants for Cl<sub>2</sub><sup>•-</sup> typically

138 1-2 orders of magnitude lower than for  $\cdot\text{OH}$ .<sup>22, 42, 46</sup> The rate constants do not appear to have been  
139 reported for reactions of  $\text{Cl}\cdot$  or  $\text{Cl}_2^{\cdot-}$  with urea or  $\text{NH}_4^+/\text{NH}_3$ . However, observations from previous  
140 work suggest that these radicals likely react rapidly with both nitrogen species. Therefore, both  
141 urea and  $\text{NH}_4^+/\text{NH}_3$  likely serve as scavengers of  $\text{Cl}\cdot$  and/or  $\text{Cl}_2^{\cdot-}$ . (**Scheme 1**,  $r_{11}$  and  $r_{12}$ ).<sup>27, 47-50</sup>

142 In addition to their effects on organic contaminant degradation, the concentration of urea or  
143  $\text{NH}_4^+/\text{NH}_3$  may affect the sequence of chloride oxidation to free chlorine (FC – primarily  $\text{HOCl}$   
144 and  $\text{OCl}^-$ , and to a lesser extent  $\text{Cl}_2$  and/or  $\text{Cl}_2\text{O}$ ) and higher oxidation states (eg.  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$   
145 ). In fresh and hydrolyzed urine, FC is formed via radical-driven or direct anodic oxidation of  $\text{Cl}^-$   
146 (**Scheme 1**,  $r_{5-10}$ ).<sup>51</sup> As noted above, urea or  $\text{NH}_4^+/\text{NH}_3$  appear likely to serve as effective  
147 scavengers of  $\text{Cl}\cdot$  and/or  $\text{Cl}_2^{\cdot-}$  in either fresh or hydrolyzed urine. This could contribute to  
148 suppression of FC formation by hindering recombination and/or disproportionation reactions  
149 involving  $\text{Cl}\cdot$  and  $\text{Cl}_2^{\cdot-}$  (several of which lead to direct formation of  $\text{Cl}_2$ )<sup>52</sup>. In hydrolyzed urine  
150 with a pH of 9,  $\text{NH}_4^+/\text{NH}_3$  ( $k_{\text{HOCl},\text{NH}_3} = 3.1 \times 10^6 \text{ M}^{-1}\text{s}^{-1} \text{ M}^{-1}\text{s}^{-1}$ )<sup>53</sup> should react with FC with an  
151 apparent second-order rate constant of  $\sim 3 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$  (not corrected for ionic strength) (**Scheme**  
152 **1**,  $r_{13}$ ). It results in an anticipated maximal pseudo-first-order FC scavenging rate constant of  $\sim 2 \times$   
153  $10^4 \text{ s}^{-1}$  (and  $t_{1/2} \sim 4 \times 10^{-5} \text{ s}$ ) at the 500 mM  $\text{NH}_4^+/\text{NH}_3$  level of freshly hydrolyzed urine (with  
154 diminishing rate constant values as  $\text{NH}_3$  volatilizes from the urine during storage). In fresh urine  
155 with a pH of 6, urea ( $k_{\text{HOCl},\text{urea}} = 0.63 \text{ M}^{-1}\text{s}^{-1}$ )<sup>54</sup> should react with FC with an apparent second-order  
156 rate constant of  $\sim 0.6 \text{ M}^{-1}\text{s}^{-1}$  (**Scheme 1**,  $r_{14}$ ). This leads to a lower, but still high pseudo-first-order  
157 FC scavenging rate constant of  $\sim 0.2 \text{ s}^{-1}$  (and  $t_{1/2} \sim 4 \text{ s}$ ). In either case, the presence of high levels  
158 of  $\text{NH}_4^+/\text{NH}_3$  or urea should contribute to suppression of the further oxidation of  $\text{HOCl}/\text{OCl}^-$  into  
159  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  (**Scheme 1**,  $r_{16-18}$ ).



160 Many reports highlight large amounts of OBPs generated from EAOPs applied to urine. While  
161 electrochemical remediation of various OBPs has been demonstrated, including alkyl halides,<sup>55, 56</sup>  
162 haloacetic acids,<sup>57</sup> nitrosamines,<sup>58</sup>  $\text{ClO}_3^-$ ,<sup>59</sup> and  $\text{ClO}_4^-$ ,<sup>60-62</sup> preventing them from forming is a  
163 preferred approach.  $\text{ClO}_4^-$  is the most challenging to remediate due to its high stability among all  
164 the OBPs generated during electrolysis of urine.  $\text{ClO}_4^-$  has a large electrochemical activation  
165 barrier for reduction to  $\text{ClO}_3^-$  of 120 kJ/mole,<sup>63</sup> which makes its reduction very sluggish (**Scheme**  
166 **1**,  $r_{21}$ ). The slow kinetics of  $\text{ClO}_4^-$  reduction accentuate the need that EAOPs not generate  
167 significant quantities of  $\text{ClO}_4^-$ , even if an OBP remediation step is applied after oxidation.

168 In this work, we show the advantages of conducting electrochemical oxidation of  
169 pharmaceuticals in fresh urine (at point of generation) as opposed to hydrolyzed (without loss of  
170  $\text{NH}_3$ ) or hydrolyzed aged urine (with loss of  $\text{NH}_3$ ). We demonstrate that urea (and/or  $\text{NH}_4^+/\text{NH}_3$ )  
171 effectively inhibits the oxidation pathway toward  $\text{ClO}_4^-$ , likely due to scavenging of  $\text{Cl}^\bullet$  and/or  
172  $\text{Cl}_2^{\bullet-}$  (**Scheme 1**,  $r_{11}$  and  $r_{12}$ ) or rapid sequestration of  $\text{HOCl}$  (**Scheme 1**,  $r_{13}$  and  $r_{14}$ ). Meanwhile,  
173 the urea in fresh urine inhibits the oxidation of pharmaceuticals much less than the  $\text{NH}_4^+/\text{NH}_3$  and  
174  $\text{HCO}_3^-/\text{CO}_3^{2-}$  in hydrolyzed urine due to urea's lower reactivity toward  $\bullet\text{OH}$  (**Scheme 1**,  $r_1$ ,  $r_3$  and  
175  $r_{20}$ ). Accordingly, the electrochemical oxidation rates of the pharmaceuticals investigated are  
176 higher in synthetic fresh urine matrixes than in synthetic hydrolyzed and hydrolyzed aged urine  
177 matrixes. Thus, this work provides a proof-of-concept for simple and safe point-source oxidation  
178 of pharmaceutical compounds in fresh human urine.

179

## 180 **2. Experimental Section**

### 181 **2.1 Chemicals and Solutions**

182        Ultrapure water (>18.2 M $\Omega$ /cm resistance) was used for preparation of all standards and test  
183 solutions. Reagent grade (99% purity or higher) (NH<sub>2</sub>)<sub>2</sub>CO, NaCl, NaHCO<sub>3</sub>, NH<sub>4</sub>OH, NH<sub>4</sub>Cl, HCl,  
184 NaClO<sub>3</sub>, NaClO<sub>4</sub>, HgCl<sub>2</sub>, Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, Na<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>, NaNO<sub>2</sub>, glycine, creatinine, uric acid, and  
185 urea obtained from Sigma-Aldrich were used for all standards and test solutions. DPD free and  
186 total chlorine test kits were obtained from Sigma-Aldrich. NaOCl (Sigma-Aldrich; 13.5%  
187 available chlorine) stock solution was calibrated every month by iodometry. Catalase (Sigma-  
188 Aldrich) was vortexed and centrifuged to remove the supernatant, then reconstituted in phosphate  
189 buffer and centrifuged again, with the process repeated 5 times to remove thymol. Analytical  
190 reference standards of cyclophosphamide (CP) (90% purity) and sulfamethoxazole (SMX) ( $\geq$  98%  
191 purity) from Sigma-Aldrich were used. Simplified synthetic fresh urine matrixes consisted of an  
192 aqueous solution of 250 mM urea, 100 mM NaCl, and either 1.92 mM CP or 0.39 mM SMX.  
193 Synthetic fresh urine matrix solutions consisted of 250 mM urea, 100 mM NaCl, 16 mM Na<sub>2</sub>SO<sub>4</sub>,  
194 24 mM NaH<sub>2</sub>PO<sub>4</sub>, 13 mM creatinine, 3 mM uric acid, and 1.92 mM CP or 0.39 mM SMX. All  
195 prepared synthetic fresh urine matrixes were at pH 6. Synthetic hydrolyzed urine matrixes  
196 consisted of an aqueous solution of 250 mM NaHCO<sub>3</sub>, 100 mM NH<sub>4</sub>Cl, and 400 mM NH<sub>4</sub>OH (i.e.,  
197 [NH<sub>4</sub><sup>+</sup>]<sub>total</sub> = 500 mM) at pH 9.35. Synthetic hydrolyzed aged urine matrixes were adapted from  
198 Udert et al.<sup>35</sup> and Hoffmann et al.<sup>16</sup>, and consisted of 250 mM NaHCO<sub>3</sub>, 100 mM NaCl, and either  
199 140 mM or 33 mM NH<sub>4</sub>OH at pH 9.02 and 8.88, respectively. Authentic fresh urine was collected  
200 at 10 A.M. and blended from 6 people, 3 males and 3 females, with different ethnic background  
201 and diets. The blended urine was pH 6.3. Electrolysis of authentic fresh urine was started  
202 immediately after the addition of 0.39 mM SMX to 40 mL of the blended urine.

## 203    **2.2 Electrolytic Cell and Electrodes**

204 A custom three-electrode electrochemical cell was used for all oxidation experiments in this  
205 work (**Figure S1**). Detailed schematic dimensions and a photograph of the cell are provided in the  
206 SI (**Figure S2**). The cell was designed to accommodate a large planar working electrode with  
207 dimensions 40 mm x 80 mm, which is held in place between the bottom of the cell and a base  
208 plate. A seal is formed with a Kalrez gasket exposing a planar surface area of the working electrode  
209 of 8.56 cm<sup>2</sup>. Planar anodes (BDD or IrO<sub>2</sub>) were used for the oxidation experiments. SAE 304  
210 stainless steel tubes were used as the counter electrodes in all oxidation experiments. An Ag/AgCl  
211 (3 M NaCl) reference electrode (BASi, West Lafayette, IN, USA) was used in all experiments. In  
212 the “undivided cell” setup, the counter electrode was immersed in the same solution as the working  
213 electrode. In the “divided cell” setup, the counter electrode was placed inside a glass tube with a  
214 12 mm O.D. porous frit at the bottom (4-8 μm pores, ACE Glass #7209 porosity E). For oxidation  
215 experiments, three counter electrodes in fritted glass tubes were used in parallel to minimize  
216 resistance and potential drop due to ionic transport through the frits.

217 Planar boron-doped diamond (BDD) electrodes were purchased from Condias GmbH. Planar  
218 Ti/IrO<sub>2</sub> electrodes were prepared by thermal decomposition of a 250 mM H<sub>2</sub>IrCl<sub>6</sub> precursor  
219 solution similar to a method described previously.<sup>35</sup> Ti sheet metal was first sandblasted and  
220 cleaned with 1 M oxalic acid for 1 hour at 95 °C. The precursor solution was spray-coated onto  
221 the Ti substrates on a hotplate held at 500 °C, and then the substrates were annealed at 500 °C for  
222 1 hr after precursor deposition.

### 223 **2.3 Electrochemical Methods**

224 All cyclic voltammetry, galvanostatic, and potentiostatic experiments were performed with a  
225 Princeton Applied Research Potentiostat/Galvanostat Model 263A.

226 Cyclic Voltammetry of Anode Reactions: Each electrode (BDD and IrO<sub>2</sub>) was sonicated in  
227 deionized water then pretreated in 40 mL 100 mM Na<sub>2</sub>SO<sub>4</sub> for 5 minutes at 3.5 V or 2 V  
228 respectively. The electrochemical cell was then thoroughly rinsed with deionized water. The  
229 matrix of interest was then added to the cell and a single scan was initiated from 0 V to 3.5 V or  
230 2.5 V respectively, and back to 0 V at a scan rate of 50 mV/s in the undivided cell setup. Nitrogen  
231 gas was bubbled through the solution for two minutes prior to and blanketed during the cyclic  
232 voltammetry.

233 Galvanostatic Oxidation of Pharmaceuticals in Urine: Electrochemical oxidations of  
234 pharmaceutical compounds were performed galvanostatically at a current density of 10 mA/cm<sup>2</sup>  
235 for 120 min (reaching 4.2 A-h/L) while the solution was stirred at 550 rpm. These experiments  
236 were conducted in a supporting electrolyte with the major constituents of synthetic fresh urine (100  
237 mM NaCl and 250 mM urea, pH 6.15) or full synthetic fresh urine matrixes (*see above*) or synthetic  
238 hydrolyzed, aged urine matrixes (i.e., [NH<sub>4</sub><sup>+</sup>/NH<sub>3</sub>] = 33 or 140 or 500 mM, [HCO<sub>3</sub><sup>-</sup>/CO<sub>3</sub><sup>2-</sup>] = 250  
239 mM and pH 9) and SMX or CP at a concentration of 0.39 mM or 1.92 mM, respectively. Based  
240 upon the suggested dosage from U.S. FDA<sup>64, 65</sup> and percentage of excretion via urine,<sup>66, 67</sup> SMX  
241 and CP will remain in human urine at concentrations of 0.975 mM and 1.92 mM, respectively.  
242 While the solubility of SMX is 610 mg/L (2.41 mM) at 37 °C,<sup>68</sup> dissolving this concentration of  
243 SMX at room temperature was difficult. Therefore, 100 mg/L SMX (0.39 mM) was used for  
244 electrolysis at room temperature. Aliquots were periodically collected, quenched with excess  
245 thiosulfate, and analyzed for target compounds and oxidation byproducts.

246 Galvanostatic Oxidation of Urine without Pharmaceuticals: Electrochemical oxidations of  
247 various urine matrixes were performed galvanostatically at a current density of 93 mA/cm<sup>2</sup> on  
248 BDD electrode for 90 min (reaching 30 A-h/L), stirred at 550 rpm. These experiments were

249 conducted in the supporting electrolytes that simulated different urine matrixes (simplified vs full  
250 urine matrixes, fresh vs. hydrolyzed, ammonia loss vs. no ammonia loss). A control experiment  
251 was conducted in NaCl solution to yield maximal oxychloride generation as a reference.

## 252 **2.4 Analytical Methods**

253 Aliquots were taken during electrolysis for analyses by ion chromatography (IC) and high-  
254 pressure liquid chromatography with ultraviolet absorbance and mass spectrometry detection  
255 (HPLC-UV-MS) (**Text S2**). pH was measured by an Apera pH60 pH tester. Free chlorine (FC),  
256 total chlorine (TC) and ClO<sub>2</sub> were measured by DPD and/or ABTS methods when electrolysis was  
257 employed in various urine matrixes (**Text S3**).

## 258 **3. Results and Discussion**

### 259 **3.1 Advantages of Decentralized Treatment of Urine**

260 Point-source electrochemical oxidation of pharmaceuticals in source-separated urine has  
261 multiple advantages compared with centralized treatment at a WWTF after it mixes with feces and  
262 other wastewater (**Table 1**). These advantages are: (1) small treatment volumes, (2) high  
263 pharmaceutical concentration, (3) absence of non-urine derived background organic carbon or  
264 other interfering matrix constituents, and (4) high electrical conductivity. Average human urine  
265 production is 1.3 L/(person·day), while average domestic wastewater discharge is two orders of  
266 magnitude higher at 148 L/(person·day).<sup>69</sup> The dilution of urine with other waste streams not only  
267 decreases the absolute concentration of pharmaceuticals, but also decreases their relative  
268 concentration compared to the total concentration of organics in the solution (due to mixing with  
269 feces, cooking oils, detergents, etc.). This domestic wastewater may be further diluted by other  
270 waste streams containing other organics (such as industrial wastewater, urban runoff, etc.) before

271 reaching a WWTF. The daily per capita load of chemical oxygen demand (COD) to domestic  
 272 wastewater from all sources (e.g., including feces, urine, greywater, etc.) is more than 6x higher  
 273 than from urine alone, and the  $COD_{\text{pharm}}/COD_{\text{total}}$  is correspondingly 3.8% for domestic wastewater  
 274 compared to 24.2% for urine (**Table 1**). Furthermore, the typical conductivity of fresh urine is two  
 275 orders-of-magnitude higher than domestic wastewater. The combination of large treatment  
 276 volumes and low conductivity for domestic wastewater streams would correspond to massive  
 277 ohmic losses in the solution, making electrochemical oxidation as a “polishing” or tertiary WWT  
 278 step even more costly.

279 **Table 1.** Comparison of relative advantages of degrading pharmaceuticals in urine before dilution with  
 280 other domestic wastewater.<sup>69, 70</sup>

Matrix	Wastewater Contribution [L/person/day] <sup>a</sup>	Conductivity [mS/cm] <sup>a</sup>	Daily Per Capita COD Load [mg O <sub>2</sub> /person/day]	Matrix COD [mg/L]	Pharm COD [mg/L]	Pharm COD/ (Pharm COD +Matrix COD)	Required Charge Passed [A·hr] <sup>b</sup>	Electricity Cost [\$/person/day] <sup>b</sup>	Electricity Cost [\$/person/year] <sup>b</sup>
Pharmaceuticals Only	--	--	2080	--	--	--	29.0	\$0.022	\$7.95
Urine (including pharmaceuticals)	1.3	160	15080	10000	1600	13.8%	210	\$0.16	\$57.60
Domestic Wastewater	148	1.8	106080	702.7	14.05	2.0%	1480	\$1.11	\$405


281 <sup>a</sup> Dilution with other wastewater increases the treatment volume and reduces the matrix conductivity by  
 282 two orders of magnitude. Pharmaceuticals are at their highest absolute and relative concentration when they  
 283 are in urine, before they are diluted by other domestic wastewater sources. <sup>b</sup> To estimate the electricity cost  
 284 of electrochemically oxidizing all organics in the matrix, chemical oxygen demand (COD) was used. The  
 285 assumptions for these calculations are an electricity cost of 0.15 \$/kWhr, a pharmaceutical concentration  
 286 of 10 mM, a COD of 5 mols O<sub>2</sub>/mol pharmaceutical, a total applied voltage of 5 V, a Faradaic efficiency  
 287 toward oxidant reaction with organics of 30%, and full mineralization of pharmaceuticals to CO<sub>2</sub>, H<sub>2</sub>O, etc.

288

### 289 3.2 Reactive Chlorine Species Scavenged by Urea

290 Cyclic voltammetry was performed in three different solutions to reveal the effects of urea on  
 291 the electrocatalytic oxidation of water (primarily to O<sub>2</sub>(g) and ·OH) and chloride (primarily to  
 292 Cl<sub>2</sub>(g), HOCl, Cl<sup>·</sup>, and Cl<sub>2</sub><sup>·-</sup>) by boron-doped diamond (BDD) and thermally decomposed iridium

293 oxide (IrO<sub>2</sub>) anodes. BDD was used as a model “non-active” electrode that only physisorbs •OH,  
294 whereas IrO<sub>2</sub> was used as a model “active” electrode that chemisorbs •OH, effectively forming a  
295 surface hydroxyl group. The three solutions chosen comprised: (1) 100 mM NaClO<sub>4</sub> to  
296 characterize the water oxidation without chloride oxidation, given that ClO<sub>4</sub><sup>-</sup> will not be further  
297 oxidized; (2) 100 mM NaCl to observe the additional current from chloride oxidation; and (3) 100  
298 mM NaCl plus 250 mM urea to observe any differences in chloride oxidation that occur with urea  
299 present. **Figure 1a, b** shows cyclic voltammograms (CV) of oxidative sweeps of these three  
300 solutions on BDD and IrO<sub>2</sub>. The CV of BDD with NaClO<sub>4</sub> shows the expected large onset potential  
301 for O<sub>2</sub>(g) evolution of 2.4 V vs SHE.<sup>71</sup> With Cl<sup>-</sup> present, the current onset potential shifts down to  
302 2.1 V vs SHE due to the lower overpotential for Cl<sub>2</sub>(g) evolution. See **Table S1** for a list of relevant  
303 thermodynamic standard and formal potentials for these reactions. In contrast to BDD, the CV of  
304 IrO<sub>2</sub> in **Figure 1b** showed a difference in the current onset potential and the magnitude of current  
305 when Cl<sup>-</sup> is present. The IrO<sub>2</sub> surface oxidizes according to IrO<sub>2</sub> + H<sub>2</sub>O ⇌ IrO<sub>3</sub> + 2H<sup>+</sup> + 2e<sup>-</sup>.<sup>72</sup> In  
306 the Cl<sup>-</sup> only solution on IrO<sub>2</sub>, the peak seen in the cathodic sweep from 1.2 V to 0 V likely  
307 corresponds to the reduction of oxidized chlorine species such as HOCl, Cl<sup>•</sup>, or Ir-O-Cl surface  
308 groups. Most importantly, the absence of this peak when urea is present in the matrix shows that  
309 urea scavenges one or more of these reactive chlorine species (RCS).



310

311 **Figure 1.** CVs in 100 mM NaClO<sub>4</sub>, 100 mM NaCl, and 100 mM NaCl + 250 mM urea on (a) BDD and (b)  
 312 IrO<sub>2</sub> anodes. On BDD, a lower onset potential of gas evolution when NaCl is present is indicative of Cl<sub>2</sub>(g)  
 313 generation. On IrO<sub>2</sub> there are a couple of reduction peaks attributable to chlorine species (HOCl, Cl<sup>-</sup> or Ir-  
 314 O-Cl surface groups), apparent in the 100 mM NaCl matrix but absent in the NaClO<sub>4</sub> case. Interestingly,  
 315 the reduction peaks are also absent when urea is added. This suggests that generated chlorine species are  
 316 scavenged by urea. (c) Concentration of cyclophosphamide (CP) during the electrolysis in simplified  
 317 synthetic fresh urine matrixes with a starting CP concentration of 1.9 mM. Inset: The chemical structure of  
 318 CP. (d) Concentration of sulfamethoxazole (SMX) during oxidation in simplified synthetic fresh urine  
 319 matrixes with a starting SMX concentration of 0.39 mM. Inset: The chemical structure of SMX. (e)  
 320 Observed pseudo-first-order rate constants for pharmaceutical degradation. Note that the degradation rates  
 321 in all conditions are fast enough to lower the concentration of pharmaceuticals by three orders of magnitude  
 322 in five hours or less. (f) Observed pseudo-first-order rate constants for SMX degradation in simplified  
 323 synthetic fresh urine, full synthetic fresh urine, and authentic fresh human urine with undivided  
 324 electrochemical cell setup. The error bars represent standard deviations about the means from triplicate  
 325 experiments.

326

327

### 328 3.3 Pseudo-First Order Kinetics and Mass Transfer

329 Most research thus far examining electrochemical oxidation of pharmaceuticals has reported  
 330 rates of pharmaceutical degradation in terms of observed pseudo-first-order rate constants. As  
 331 highlighted by Zöllig et al., these first-order kinetics should only be expected in galvanostatic



332 electrolysis for mass-transfer-limited reactions (assuming only heterogeneous reactions).<sup>34</sup>  
333 Therefore, the pseudo-first-order rate constants for pharmaceutical degradation are highly  
334 dependent on the geometry and the mass transport in the electrochemical setup. A mass-transfer  
335 limited observed pseudo-first-order rate constant is directly proportional to the planar surface-area  
336 of the anode and inversely proportional to the volume of the solution. In this work, an effort was  
337 made to choose reasonable values for the ratio of the electrode surface area to electrolyte volume  
338 ( $A/V$ ) based on scale-up to a practical device. The electrochemical setup used in this work (**Figure**  
339 **S1**) has an  $A/V$  of  $0.21 \text{ cm}^{-1}$  and is magnetically stirred. The hydrodynamic flow pattern in the  
340 magnetically stirred reactor is similar<sup>73</sup> to the flow pattern in a rotating disk electrode (RDE),<sup>74</sup>  
341 where the mass-transfer limited reaction rate is proportional to  $Re^{1/2}$  (Reynolds number,  $Re =$   
342  $\omega r^2/\nu$ ). In order to assess if the electrochemical oxidation of pharmaceuticals is mass-transfer  
343 limited in our stirred electrochemical setup, we conducted galvanostatic oxidation experiments  
344 over a wide range of Reynolds number,  $150 < Re < 10,000$ . We found that the observed first-  
345 order rate constant for CP degradation varied linearly with  $Re^{1/2}$  (**Figure S3**). This confirms that  
346 the experiments here are mass-transfer limited for CP. All experiments were performed with stir-  
347 bar radius ( $r$ ) and rotation rates ( $\omega$ ) corresponding to  $Re = 1,600$ . This yields a mass-transfer  
348 limited electrolysis rate of  $0.022 \text{ min}^{-1}$  (i.e.,  $0.102 \text{ cm/min}$ ) for CP.

349 To determine what pseudo-first-order rate constants are practical for a real device, we modeled  
350 expected degradation rates for various rate constants as shown in **Figure S4**. A pseudo-first order  
351 rate constant of  $0.01 \text{ min}^{-1}$  or greater is required to lower pharmaceutical concentrations by at least  
352 three orders of magnitude in a 12-hour period, which is a reasonable residence time for a practical  
353 at-home situation. This corresponds to a geometry-normalized pseudo-first order rate constant

354 (based on  $A/V$ ) of at least 0.05 cm/min to degrade pharmaceuticals at a rate reasonable for a scaled-  
355 up device.

### 356 **3.4 Electrolysis of Pharmaceuticals**

357 Galvanostatic oxidation in fresh-urine matrixes: A series of galvanostatic oxidations were  
358 performed with BDD and  $\text{IrO}_2$  anodes. The experiments were performed on both anodes for two  
359 pharmaceuticals, SMX and CP (see chemical structures in **Figure 1c, d** insets). SMX and CP were  
360 chosen as test compounds because of their large differences in reactivity toward free chlorine (FC).  
361 SMX has a relatively high bimolecular rate constant with FC of  $\sim 10^3 \text{ M}^{-1}\text{s}^{-1}$  at circumneutral pH,<sup>75</sup>  
362 while we measured CP to be essentially non-reactive with FC (see **Text S4** for experimental  
363 details) (**Scheme 1**,  $r_{15}$ ). Galvanostatic oxidations were performed in both an undivided  
364 electrochemical cell (working electrode (WE) and counter electrode (CE) in same compartment)  
365 and divided electrochemical cell (WE and CE separated by a frit) to test if cathodic reactions had  
366 any influence on the degradation pathway (see **Figure S1a** and **S1b**). The concentrations of SMX  
367 and CP were lowered by two orders-of-magnitude after two hours of electrolysis at 10 mA/cm<sup>2</sup> for  
368 all conditions (**Figure 1c** and **1d**). This corresponds to geometry normalized pseudo-first order  
369 rate constants greater than 0.1 cm/min for all conditions as shown in **Figure 1e**. As shown in  
370 **Figure 1f**, observed pseudo-first order rate constants of SMX degradation were lower for synthetic  
371 fresh urine matrixes and authentic fresh urine. However, the reactions remained sufficiently fast  
372 to degrade SMX by four orders of magnitude in  $\sim 8$  hours as illustrated in **Figure S4**.

373 The rate constants for oxidation of both pharmaceuticals by both electrodes are similar in  
374 simplified synthetic fresh urine matrixes (i.e., urea +  $\text{Cl}^-$ ). This suggests that mass transfer to the  
375 electrode surface is the dominant factor limiting the degradation rates (*see above*). For  $Re =$   
376  $10,000$ , pseudo-first-order degradation rate constants up to 0.25 cm/min were achieved. However,

377 stir speeds corresponding to a  $Re$  number of 1,600 were used for the experimental data shown in  
378 **Figure 1**, since they are easy to achieve in electrochemical devices.


379 For the divided cell setup, a pH gradient is established because the oxygen evolution reaction  
380 (OER) at the anode generates  $H^+$  while the hydrogen evolution reaction (HER) at the cathode  
381 generates  $OH^-$ . On average, the pH was stabilized to 1.8 for  $IrO_2$  and 2.3 for BDD in the anode  
382 chamber and 12.5 in the cathode chamber for both electrodes. Furthermore, this gradient is quickly  
383 established. Passing  $10\text{ mA/cm}^2$  for 5 mins ( $\sim 0.2\text{ A}\cdot\text{hr/L}$ ) was sufficient to establish this gradient  
384 of  $\sim 10$  pH units for both BDD and  $IrO_2$ . Moreover, the electrolysis rates of CP and SMX did not  
385 show significant differences in divided and undivided cell setups. This suggests that there is little  
386 to no effect of cathodic reactions (possibly reducing homogeneous oxidants) on the degradation of  
387 pharmaceuticals, which is consistent with the above finding of mass-transfer limited degradation  
388 kinetics at the anode. In addition, the effect of the bulk solution pH (a drop from 6 in the undivided  
389 cell to 2 in the divided cell) had no appreciable impact on degradation rates. This could be due to  
390 the fact that the local pH at the anode surface in the undivided cell may be much lower than the  
391 bulk pH due to  $H^+$  generation at the anode.

392 *Differences between Synthetic Fresh, Hydrolyzed, and Hydrolyzed-Aged Urine Matrixes:* The  
393 electrolysis rates of CP and SMX were also investigated in synthetic hydrolyzed and synthetic  
394 hydrolyzed aged urine matrixes and compared to a reference mass-transfer limited rate (**Figure**  
395 **2a**). Sketches of concentration profiles adjacent to the anode surface are shown in **Figure 2b** to  
396 illustrate the differences between kinetic limitation (gradient A), mass-transport limitation due to  
397 heterogeneous reactions (direct electron transfer and reactions with adsorbed  $\cdot OH$  or RCS) (gradient  
398 B), and mass-transport limitation due to the combination of heterogeneous reactions and near-  
399 anode-surface homogeneous reactions with desorbed  $\cdot OH$ , RCS, or other homogeneous oxidants

400 (gradients C and D). As noted above, the mass-transfer limited electrolysis rate for CP was  
401 determined to be  $0.022 \text{ min}^{-1}$ . Given CP's slow reaction with RCS and the short lifetime of  $\cdot\text{OH}$ ,  
402  $0.022 \text{ min}^{-1}$  likely corresponds to the mass-transport limited rate with primarily heterogeneous  
403 reactions. Desorbed  $\cdot\text{OH}$  may exist in solution, but the homogeneous reaction zone where it may  
404 react with CP is less than  $1 \mu\text{m}$  in thickness,<sup>76</sup> which is small compared to the stagnant layer  
405 thickness of  $>20 \mu\text{m}$ . Additionally, the linear relationship between  $k_{\text{obs}}$  and  $Re^{1/2}$  also suggests the  
406 obtained mass-transfer limiting rate corresponds to gradient B.

407 As shown in **Figure 2a**, the degradation rates of CP were mass-transfer limited in simplified  
408 and full synthetic fresh urine matrixes – likely due to the electro-generation of  $\cdot\text{OH}$  on the BDD  
409 anode. In comparison, the electrolysis rates of SMX exceeded the heterogeneous reaction mass-  
410 transfer limiting rate (gradient B). This suggests SMX degradation also occurs through  
411 homogeneous reactions involving either reactive chlorine species (RCS – a collective sum of FC  
412 and chlorine radicals) or other homogeneous oxidants (**Figure 2b**, Gradient C or D). In contrast,  
413 the electrolysis rates of CP and SMX were significantly decreased below the mass-transfer limiting  
414 rates in synthetic hydrolyzed urine matrixes amended with varying  $\text{NH}_4^+/\text{NH}_3$  levels (to reflect  
415 different degrees of aging). This suggests that  $\text{HCO}_3^-/\text{CO}_3^{2-}$  (present at the same 250 mM  
416 concentration in each hydrolyzed urine matrix) acts as a dominant  $\cdot\text{OH}$  and  $\text{Cl}^+/\text{Cl}_2^{\cdot-}$  scavenger in  
417 such matrixes. This results in the formation of  $\text{CO}_3^{\cdot-}$ , which typically reacts with organic  
418 contaminants  $\sim 10^3$ -fold slower than  $\cdot\text{OH}$  or  $\text{Cl}^+$  and  $\sim 10$ -fold slower than  $\text{Cl}_2^{\cdot-}$  (*see above*).  
419 Furthermore, the degradation rates of both pharmaceuticals in such matrixes were invariant with  
420 changes in the concentration of  $\text{NH}_4^+/\text{NH}_3$ , consistent with the apparent low reactivity of  
421  $\text{NH}_4^+/\text{NH}_3$  toward  $\text{CO}_3^{\cdot-}$ .<sup>77</sup> This likewise suggests that RCS do not contribute significantly to CP  
422 or SMX oxidation in the hydrolyzed urine matrixes, because increasing concentrations (33-500


423 mM) of  $\text{NH}_4^+/\text{NH}_3$  would have been expected to increase RCS scavenging efficiency, and  
 424 consequently decrease rates of pharmaceutical degradation if RCS were predominant oxidants.  
 425 Furthermore, the electrolysis of CP and SMX appears to be kinetically limited in hydrolyzed urine  
 426 matrixes (**Figure 2b**, Gradient A) for BDD anodes. As a result, it may be advantageous to  
 427 electrochemically oxidize pharmaceuticals in fresh urine rather than in hydrolyzed urine for faster  
 428 pharmaceutical removal.



429  
 430 **Figure 2.** (a) Observed and geometry-normalized pseudo-first-order rate constants for pharmaceutical  
 431 degradation on BDD electrodes with undivided cell setup in: (1) simplified urine matrixes (250 mM urea  
 432 and 100 mM  $\text{Cl}^-$ , pH 6.15); (2) synthetic full fresh urine matrixes (see **Chemicals and Solutions**, pH 5.87);  
 433 (3) hydrolyzed, un-aged urine matrixes (100 mM  $\text{Cl}^-$ , 500 mM  $\text{NH}_4^+$  and 250 mM  $\text{HCO}_3^-$ , pH 9.35); (4)  
 434 hydrolyzed, aged urine matrixes adapted from Udert et al.<sup>35</sup> (100 mM  $\text{Cl}^-$ , 140 mM  $\text{NH}_4^+$  and 250 mM  
 435  $\text{HCO}_3^-$ , pH 9.02); and (5) hydrolyzed, aged urine matrixes adapted from Hoffmann et al. (100 mM  $\text{Cl}^-$ , 33  
 436 mM  $\text{NH}_4^+$  and 250 mM  $\text{HCO}_3^-$ , pH 8.88). The dotted line represents the mass-transfer limiting rate of  
 437 pharmaceutical degradation obtained from **Figure S3**. The electrolytes (40 mL) were stirred at 500 rpm.  
 438 The applied current density was 10 mA/cm<sup>2</sup>. The error bars represent standard deviations about the means  
 439 from triplicate experiments. (b) Possible concentration gradients of pharmaceuticals in the stagnant layer  
 440 (assuming constant bulk concentration). Gradient A: oxidation that is kinetically limited by the  
 441 heterogeneous reactions at the anode surface (i.e., via direct anodic oxidation and surface bound oxidants).  
 442 Gradient B: the oxidation is mass-transfer limited and the concentration is zero at the anode surface, but  
 443 increases in solution. Gradient C: the oxidation is mass-transfer limited, but in addition to heterogeneous  
 444 reactions, oxidants generated at the anode desorb, diffuse outward, and react homogeneously with the  
 445 pharmaceutical to drive the concentration to zero some distance away from the surface. Gradient D: the  
 446 oxidation is mass-transfer limited with a larger homogeneous reaction enhancement than gradient C.  
 447

### 448 3.5 Generation of Oxidation Byproducts

449 The rates of oxidation byproduct generation in full synthetic fresh urine matrixes were  
450 compared for each combination of anode and cell configuration as shown in **Figure 3**. Both  $\text{ClO}_4^-$   
451 and  $\text{ClO}_3^-$  were often found to be near or below the detection limits (i.e., 2  $\mu\text{M}$ ) for the ion  
452 chromatography techniques used in these experiments. The detection limits for both  $\text{ClO}_3^-$  and  
453  $\text{ClO}_4^-$  were higher than in pure water due to the high concentration of  $\text{Cl}^-$  in urine matrixes. No  
454  $\text{ClO}_4^-$  was measured in matrixes oxidized by the  $\text{IrO}_2$  anode, which is similar to what has been  
455 reported previously.<sup>16, 31</sup>  $\text{ClO}_4^-$  was formed in the matrixes oxidized on the BDD anode, but at  
456 much lower concentrations than what has been reported previously.<sup>16, 35</sup> Additionally, the  $\text{ClO}_4^-$   
457 measured on the BDD electrode was at a lower concentration than the  $\text{ClO}_3^-$ , which is consistent  
458 with other reports.<sup>16, 35</sup> Nitrate ( $\text{NO}_3^-$ ) (**Figure 3c**) and nitrite ( $\text{NO}_2^-$ ) (**Figure 3d**) generation were  
459 found to be higher on the  $\text{IrO}_2$  electrode than the BDD electrode, though in  $\text{IrO}_2$  divided cell  
460 experiments,  $\text{NO}_2^-$  generation was below the detection limit (5  $\mu\text{M}$ ). These oxidized nitrogen  
461 anions could come from the oxidation of urea, creatinine, uric acid and/or the oxidation of CP or  
462 SMX. Reaction pathways involving radical-driven generation of reactive nitrogen species from  
463  $\text{NO}_3^-$  or  $\text{NO}_2^-$  have been shown to lead to potentially harmful nitrated and nitrosated byproducts.<sup>78,</sup>  
464 <sup>79</sup> The suppression of  $\text{NO}_2^-$  formation when using the  $\text{IrO}_2$  anode in the divided cell configuration  
465 indicates that such pathways would not be active or would at least be diminished and represents a  
466 potential advantage of operating in this mode.



467

468 **Figure 3.** Evolution of inorganic oxidation byproducts showing concentrations of (a) ClO<sub>4</sub><sup>-</sup>, (b) ClO<sub>3</sub><sup>-</sup>, (c)  
 469 NO<sub>3</sub><sup>-</sup>, and (d) NO<sub>2</sub><sup>-</sup> during electrolysis at 10 mA/cm<sup>2</sup> on BDD and IrO<sub>2</sub> anodes in the undivided and divided  
 470 setups. Results are from oxidation of full synthetic fresh urine matrixes amended with 1.9 mM CP and 0.39  
 471 mM SMX. The error bars represent standard deviations from triplicate experiments. It is notable that the  
 472 inorganic oxidation byproduct concentrations observed here in full synthetic fresh urine matrixes are  
 473 substantially lower than what have been previously reported in authentic hydrolyzed aged urine.<sup>16, 35</sup>

474

475 *Inhibition of Oxychloride Formation Increases with Increased Urea or NH<sub>4</sub><sup>+</sup>/NH<sub>3</sub>:* The levels

476 of generated OBPs shown in **Figure 3** are substantially lower than in previous studies of authentic

477 hydrolyzed aged urine electrolysis.<sup>16, 35</sup> Therefore, further experiments were undertaken in several

478 matrixes and at extended electrolysis time to evaluate potential causes of the lower rates of

479 formation of OBPs (**Figure 4**). Fresh urine has an average concentration of 250 mM urea,<sup>36</sup>


480 whereas hydrolyzed urine should exhibit maximal concentrations of 500 mM NH<sub>4</sub><sup>+</sup>/NH<sub>3</sub> and 250

481 mM HCO<sub>3</sub><sup>-</sup> after urea hydrolysis. Previous studies that have examined the treatment of authentic

482 hydrolyzed aged urine have typically utilized much lower NH<sub>4</sub><sup>+</sup>/NH<sub>3</sub> concentrations (e.g., 34 mM<sup>16</sup>

483 and 109 mM<sup>35</sup>) indicating substantial ammonia loss during storage (aging). As shown in **Figure**

484 4,  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  generation were increasingly inhibited as dissolved nitrogen concentration  
 485 increased. For example, a  $10^3$ -fold decrease in  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  generation was observed for a  
 486 matrix of 100 mM  $\text{Cl}^-$  and 250 mM urea compared to 100 mM  $\text{Cl}^-$  alone. A full synthetic fresh  
 487 urine matrix containing the other primary constituents of urine (citrate, creatinine, uric acid,  $\text{SO}_4^{2-}$   
 488 , and  $\text{H}_2\text{PO}_4^-$ ) also showed exceptionally low  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  generation. A matrix representing  
 489 hydrolyzed (but not aged) urine (100 mM  $\text{Cl}^-$ , 500 mM  $\text{NH}_4^+$ , and 250mM  $\text{HCO}_3^-$ ) yielded a  
 490 roughly  $10^2$ -fold lower  $\text{ClO}_3^-$  concentration than 100 mM  $\text{Cl}^-$  alone, whereas  $\text{ClO}_4^-$  levels  
 491 generated were similar to those observed in the presence of 250 mM urea. The dashed lines in  
 492 **Figure 4** indicate concentrations 100x higher than the suggested drinking water limits for each  
 493 oxychloride species. Assuming that urine is typically diluted by a factor of greater than 100 in  
 494 transit to WWTFs, these lines are intended to represent thresholds below which  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$   
 495 levels would not exceed the WHO drinking water guidelines of 700  $\mu\text{g/L}$  for  $\text{ClO}_3^-$  or 70  $\mu\text{g/L}$  for  
 496  $\text{ClO}_4^-$  even for a “worst-case” scenario of minimal WWTF effluent dilution such as direct potable  
 497 reuse.<sup>80</sup> As evident from **Figure 4**,  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  levels in all of the matrixes containing low or  
 498 no  $\text{NH}_4^+/\text{NH}_3$  exceeded these thresholds, whereas  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  levels in the high  $\text{NH}_4^+/\text{NH}_3$   
 499 and urea-containing matrixes were below the thresholds (except for  $\text{ClO}_3^-$  in the high  $\text{NH}_4^+/\text{NH}_3$   
 500 matrix at the highest values of charge passed).



501




502 **Figure 4.** OBP formation in galvanostatic electrolysis experiments undertaken over extended times  
503 compared to experiments from which the Figure 3 data were obtained. Concentrations of generated (a)  
504  $\text{ClO}_3^-$  and (b)  $\text{ClO}_4^-$  were measured for various matrixes treated using a BDD anode in the undivided setup.  
505 For the matrixes containing  $\text{NH}_4^+/\text{NH}_3$ , the pH was 9–10. For the matrixes containing only  $\text{Cl}^-$  and/or urea,  
506 the pH was 6–7. Galvanostatic treatments were performed for 90 mins at a current density of 93  $\text{mA}/\text{cm}^2$   
507 for a final charge passed of 30  $\text{A}\cdot\text{hr}/\text{L}$ . The dashed lines indicate concentrations 100x higher than suggested  
508 drinking water limits for each oxychloride species (see accompanying discussion in the main text).  
509

510 *Mechanism of Inhibition of Oxychloride Formation:* In a chloride solution, oxidation of  $\text{Cl}^-$  to  
511  $\text{HOCl}/\text{OCl}^-$  is expected to proceed through direct oxidation or reaction with  $\cdot\text{OH}$  at or near the  
512 electrode surface (**Scheme 1**,  $r_{5-10}$ ).<sup>15, 81</sup> Subsequently,  $\text{HOCl}/\text{OCl}^-$  is oxidized at or near the BDD  
513 electrode surface via direct electron transfer and/or reaction with  $\cdot\text{OH}_{\text{ads}}$  to form  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$   
514 (**Scheme 1**,  $r_{16-18}$ ).<sup>51, 82</sup> In this study, we have shown that increasing urea or  $\text{NH}_4^+/\text{NH}_3$  inhibits the  
515 formation of  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$ . We hypothesize that high urea or  $\text{NH}_4^+/\text{NH}_3$  concentrations  
516 effectively prevent oxychloride formation by: (1) scavenging chlorine radical species (**Scheme 1**,  
517  $r_{11}$  and  $r_{12}$ ) and/or (2) reacting with  $\text{HOCl}/\text{OCl}^-$  and thereby sequestering chlorine in the form of  
518 organic chloramines (N-chlorinated urea) or inorganic chloramines ( $\text{NH}_2\text{Cl}$ ,  $\text{NHCl}_2$ , and/or  $\text{NCl}_3$ )  
519 (**Scheme 1**,  $r_{13}$  and  $r_{14}$ ). Either pathway would block key steps in the pathways of  $\text{Cl}^-$  oxidation to  
520  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$ .

521 Free chlorine (FC; comprising  $\text{Cl}_2\text{O}$ ,  $\text{HOCl}$ ,  $\text{OCl}^-$  and  $\text{Cl}_2$ ), total chlorine (TC; comprising FC  
522 and chloramines), and chlorine dioxide ( $\text{ClO}_2$ ) in bulk solution were quantified in full synthetic  
523 fresh urine and various synthetic hydrolyzed urine matrixes to explore the mechanism whereby  
524  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  formation is inhibited (**Figure 5**). The key observations from these measurements  
525 are: (1)  $\text{ClO}_2$  was not detected at measurable concentrations in any of the matrixes investigated,  
526 consistent with the hypothesized action of urea or  $\text{NH}_4^+/\text{NH}_3$  on RCS involved in steps preceding  
527 formation of  $\text{ClO}_2$  in the  $\text{Cl}^-$  to  $\text{ClO}_4^-$  oxidation sequence (e.g.,  $\text{Cl}^\cdot$ ,  $\text{Cl}_2^{\cdot-}$ ,  $\text{ClO}^\cdot$ , or FC); (2) no FC  
528 was measurable in the bulk solution in any of the matrixes; (3) high  $\mu\text{M}$  to low  $\text{mM}$  levels of

529 chloramine species (measured as the difference in TC and FC values) were present in each matrix,  
530 confirming that FC (once formed) was consumed by urea or  $\text{NH}_4^+/\text{NH}_3$  to form chloramine species;  
531 and importantly (4) lower concentrations of chloramines were generated in the presence of higher  
532 concentrations of  $\text{NH}_4^+/\text{NH}_3$  or urea. This last observation indicates that FC generation (followed  
533 by chloramine formation) is faster at lower concentrations of  $\text{NH}_4^+/\text{NH}_3$ . This suggests that at  
534 higher  $\text{NH}_4^+/\text{NH}_3$  concentrations, the reaction between  $\text{Cl}^\bullet/\text{Cl}_2^{\bullet-}$  and  $\text{NH}_4^+/\text{NH}_3$  to generate  $\text{NH}_2^\bullet$   
535 (**Scheme 1**,  $r_{12}$ ) out-competes the reactions between  $\text{Cl}^\bullet/\text{Cl}_2^{\bullet-}$ ,  $^\bullet\text{OH}$ , and  $\text{H}_2\text{O}$  to generate  $\text{HOCl}$   
536 (**Scheme 1**,  $r_{8-10}$ ). The generated  $\text{NH}_2^\bullet$  is then scavenged by dissolved  $\text{O}_2$ ,<sup>41</sup>  $^\bullet\text{OH}$ ,<sup>83</sup>  $\text{CO}_3^{\bullet-}$ ,<sup>84</sup> etc.  
537 without formation of chloramines. A satisfactory explanation must also reconcile the fact that the  
538 rates of generation of  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  were found to be similar in NaCl-only electrolyte (no urea,  
539 no ammonium, no bicarbonate, etc.) and in synthetic hydrolyzed urine with low  $\text{NH}_4^+/\text{NH}_3$   
540 concentration (33 mM  $\text{NH}_4^+$ , 250 mM  $\text{HClO}_3^-$ ) (**Figure 4**), even though bulk-solution FC was  
541 effectively sequestered as chloramine in the latter matrix (**Figure 5b**).



542

543 **Figure 5.** Concentration profiles of various chlorine species during electrolysis on the BDD anode in four  
 544 different matrixes. Starting from a baseline solution 100 mM Cl<sup>-</sup>, 33 mM NH<sub>4</sub><sup>+</sup>, 250 mM HCO<sub>3</sub><sup>-</sup>, the four  
 545 solutions were: (a) baseline solution at pH 6.75. (b) baseline solution at pH 8.88; (c) baseline solution with  
 546 high ammonium (500 mM NH<sub>4</sub><sup>+</sup>) at pH 9.35; (d) Full synthetic fresh urine matrix (no ammonium and  
 547 bicarbonate but with urea, creatine, uric acid, etc.) at pH 5.87). The current densities were 93.3 mA/cm<sup>2</sup>;  
 548 the stir rate was 500 rpm. FC and ClO<sub>2</sub> were not measurable in any of the four matrixes investigated. FC  
 549 measurements via DPD were verified by ABTS in matrixes (a) and (b). The measurement of total chlorine  
 550 via DPD was checked by ABTS in matrix (a). Potential interference of H<sub>2</sub>O<sub>2</sub> with the measurements of TC  
 551 was investigated by pretreating diluted samples with catalase to decompose any H<sub>2</sub>O<sub>2</sub> that may have been  
 552 present. The absence of any effect from catalase treatment indicates that H<sub>2</sub>O<sub>2</sub> was not present at  
 553 concentrations sufficient to interfere with TC measurements. Error bars represent standard deviation about  
 554 the means from triplicate experiments.  
 555

556 Taken together, these observations suggest that: (1) generation of ClO<sub>3</sub><sup>-</sup> and ClO<sub>4</sub><sup>-</sup> in these  
 557 systems involves oxidation of FC at or near the anode surface (as opposed to the bulk solution),

558 which is consistent with DFT calculations in previous work;<sup>51, 82, 85</sup> (2) lower levels of FC  
559 formation for high urea and  $\text{NH}_4^+/\text{NH}_3$  concentrations are linked to lower levels of  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$   
560 formation; and (3) suppression of  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  formation by urea and  $\text{NH}_4^+/\text{NH}_3$  derives from  
561 their  $\text{Cl}^\bullet$  and/or  $\text{Cl}_2^{\bullet-}$  scavenging effects at or near the anode interface that precede formation of  
562  $\text{HOCl}/\text{OCl}^-$  (**Scheme 1**,  $r_{11-12}$ ), rather than from FC scavenging effects in bulk solution or at the  
563 interface (**Scheme 1**,  $r_{16}$ ). Considering the much lower reactivity of urea than  $\text{NH}_4^+/\text{NH}_3$  toward  
564  $^\bullet\text{OH}$  (**Text S1**), scavenging of  $^\bullet\text{OH}$  is unlikely to be the primary mechanism for the suppression of  
565 oxychloride formation. This also points to scavenging of  $\text{Cl}^\bullet$  or  $\text{Cl}_2^{\bullet-}$  involved in FC formation as  
566 a more likely explanation for the similar effects of urea and  $\text{NH}_4^+/\text{NH}_3$  on  $\text{ClO}_4^-$  formation, and  
567 the even somewhat greater effectiveness of urea in suppressing  $\text{ClO}_3^-$  formation. Finally, the fact  
568 that similar amounts of  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$  are formed in both NaCl-only and low  $\text{NH}_4^+/\text{NH}_3$  (**Figure**  
569 **4**) solutions suggests that  $\text{NH}_4^+/\text{NH}_3$  becomes depleted near the anode surface at low  
570 concentrations. This shuts-down the amino radical pathway (**Scheme 1**,  $r_{11-12}$ ) leaving  $\text{Cl}^\bullet$  or  $\text{Cl}_2^{\bullet-}$   
571 to form  $\text{HOCl}$  (**Scheme 1**  $r_{6-10}$ ), which is then oxidized to form  $\text{ClO}_3^-$  and  $\text{ClO}_4^-$ .

572 The use of appropriately-selective probe compounds for quantification of  $\text{Cl}^\bullet$ ,  $\text{Cl}_2^{\bullet-}$ , and/or  $\text{ClO}^\bullet$   
573 could provide more definitive evidence of the relative effects of urea and  $\text{NH}_4^+/\text{NH}_3$  on chlorine  
574 radical scavenging. Unfortunately, the probe compounds most commonly accepted for such uses  
575 in advanced oxidation processes, such as nitrobenzene,<sup>86-88</sup> benzoic acid,<sup>89</sup> and 1,4-  
576 dimethoxybenzene,<sup>90, 91</sup> are unsuitable for electrolysis in either divided or undivided cells due to  
577 potential artifacts from their direct oxidation on anodes.<sup>92-96</sup> Overall, these results indicate that the  
578 protective effect of ammonia in mitigating oxychloride formation during electrolysis of hydrolyzed  
579 aged urine is likely to be lower than that afforded by urea in fresh urine due to ammonia losses  
580 following urea hydrolysis.

581

## 582 **4. Conclusion**

583 This work demonstrates that urea (or  $\text{NH}_4^+/\text{NH}_3$  from hydrolyzed urea) at the concentrations  
584 present in human urine can suppress the pathway(s) of  $\text{Cl}^-$  oxidation to the oxychlorides  $\text{ClO}_3^-$  and  
585  $\text{ClO}_4^-$  during EAOPs. This fortuitous effect greatly inhibits the formation of the highly stable  $\text{ClO}_3^-$   
586 and  $\text{ClO}_4^-$  ions, which are two of the most recalcitrant oxidation byproducts of EAOPs. The data  
587 show that pharmaceuticals could be degraded to less than 5% of their starting concentrations with  
588 less than 10  $\mu\text{M}$   $\text{ClO}_4^-$  and 100  $\mu\text{M}$   $\text{ClO}_3^-$  generated following 2 hours of electrolysis in matrixes  
589 containing 250 mM urea. These data demonstrate the feasibility of devices that eliminate  
590 pharmaceuticals in urine at the source of generation while generating minimal oxidation  
591 byproducts. "Non-active" BDD<sup>15</sup> has been the anode of choice for EAOPs because of high  
592 oxidizing power, but is prohibitively expensive to use in a practical device. This work  
593 demonstrates that "active"  $\text{IrO}_2$ <sup>15</sup> is sufficiently oxidizing to degrade cyclophosphamide (a  
594 particularly recalcitrant pharmaceutical) in simplified synthetic fresh urine matrixes at reasonably  
595 high rates of  $\sim 0.1$  cm/min. Therefore, it highlights a large opportunity for the development of both  
596 "non-active" and "active" low-cost anodes that have long service lifetime. Device development  
597 based on this chemistry could provide an important contribution to mitigating the release of  
598 pharmaceuticals and other contaminants into the environment.

599

## 600 **Associated Content**

601 **Supporting Information.** Includes calculated  $\cdot\text{OH}$ -scavenging rates in various matrixes,  
602 analytical methods for IC and HPLC-UV-MS, the procedure used to measure CP/HOCl reaction

603 kinetics, procedures for measurement of free and total chlorine, electrochemical cell schematics,  
604 results from mass transfer experiments, modeling of degradation rates for different pseudo-first-  
605 order rate constants, and tables of relevant electrochemical and chemical reactions.

## 606 **AUTHOR INFORMATION**

### 607 **Corresponding Author**

608 Email: h2@uw.edu

### 609 **Author Contributions**

610 These authors contributed equally: James A. Clark, Yuhang Yang. H.W.H. conceived the effort and  
611 supervised the execution of the research. J.A.C. designed the electrochemical cell, conceived of  
612 the experiments, and analyzed/plotted the data using custom python scripts. Y.Y. executed and  
613 designed experiments and analyzed the HPLC-UV-MS and IC data and developed python code.  
614 N.C.R. assisted in the execution of experiments and python code development. M.C.D. contributed  
615 knowledge and advice related to analytical methods and solution chemistry of free halogens,  
616 oxychlorides, and reactive oxygen and halogen species. All authors discussed the results and  
617 contributed to the final manuscript. All authors have given approval to the final version of the  
618 manuscript.

### 619 **Funding Sources**

620 We acknowledge primary financial support from the Rehnberg endowment.

### 621 **Acknowledgment**

622 We thank Prof. Ed Kolodziej (University of Washington-Tacoma and the UW Center for Urban  
623 Waters) for helpful scientific discussions. We also thank Prof. Ilwhan Oh (Kumoh National  
624 Institute of Technology, Korea) for useful discussions about cell design. We thank Dr. Martin  
625 Sadilek (University of Washington, Department of Chemistry) for training and helpful discussion  
626 on HPLC-UV-MS. We also thank J. Sean Yeung (University of Washington, Department of Civil  
627 and Environmental Engineering) for training and helpful discussion on IC. Additionally, we thank  
628 Jesse Yu (University of Washington, Department of Pharmaceutics) for helpful discussions about  
629 elimination routes for pharmaceuticals.

## 630 **References**

- 631 1. Luo, Y.; Guo, W.; Ngo, H. H.; Nghiem, D. L.; Hai, I. F.; Zhang, J.; Liang, S.; Wang, C.  
632 X., A review on the occurrence of micropollutants in the aquatic environment and their fate and  
633 removal during wastewater treatment. *The Science of the total environment* **2014**, 473-474, 619-  
634 641.
- 635 2. Calero-Caceres, W.; Melgarejo, A.; Colomer-Lluch, M.; Stoll, C.; Lucena, F.; Jofre, J.;  
636 Muniesa, M., Sludge As a Potential Important Source of Antibiotic Resistance Genes in Both the  
637 Bacterial and Bacteriophage Fractions. *Environmental Science & Technology* **2014**, 48 (13), 7602-  
638 7611.
- 639 3. Gerrity, W. D.; Benotti, J. M.; Reckhow, A. D.; Snyder, A. S., Pharmaceuticals and  
640 Endocrine-Disrupting Compounds in Drinking Water. In *Biophysico-Chemical Processes of*  
641 *Anthropogenic Organic Compounds in Environmental Systems: Xing/Anthropogenic Organic*  
642 *Compounds*, John Wiley & Sons, Inc.: 2011; pp 233-249.
- 643 4. Chong, M. N.; Jin, B.; Chow, C. W. K.; Saint, C., Recent developments in photocatalytic  
644 water treatment technology: A review. *Water Research* **2010**, 44 (10), 2997-3027.
- 645 5. Moreira, C. F.; Boaventura, A. R. R.; Brillas, E.; Vilar, J. P. V. t., Electrochemical  
646 advanced oxidation processes: A review on their application to synthetic and real wastewaters.  
647 *Applied Catalysis B: Environmental* **2017**, 202.
- 648 6. Panizza, M.; Cerisola, G., Direct and mediated anodic oxidation of organic pollutants.  
649 *Chemical Reviews* **2009**, 109 (12), 6541-6569.
- 650 7. Barazesh, J. M.; Prasse, C.; Sedlak, D. L., Electrochemical transformation of trace organic  
651 contaminants in the presence of halide and carbonate ions. *Environmental science & technology*  
652 **2016**, 50 (18), 10143-10152.
- 653 8. Ciriaco, L.; Anjo, C.; Pacheco, M. J.; Lopes, A.; Correia, J., Electrochemical degradation  
654 of Ibuprofen on Ti/Pt/PbO<sub>2</sub> and Si/BDD electrodes. *Electrochimica Acta* **2009**, 54 (5), 1464-1472.

- 655 9. Domínguez, J. R.; González, T.; Palo, P.; Sánchez-Martín, J.; Rodrigo, M.; Sáez, C.,  
656 Electrochemical degradation of a real pharmaceutical effluent. *Water, Air, & Soil Pollution* **2012**,  
657 223 (5), 2685-2694.
- 658 10. Sopaj, F.; Rodrigo, A. M.; Oturan, N.; Podvorica, I. F.; Pinson, J.; Oturan, A. M., Influence  
659 of the anode materials on the electrochemical oxidation efficiency. Application to oxidative  
660 degradation of the pharmaceutical amoxicillin. *Chemical Engineering Journal* **2015**, 262.
- 661 11. von Gunten, U., Oxidation processes in water treatment: are we on track? *Environmental*  
662 *science & technology* **2018**, 52 (9), 5062-5075.
- 663 12. Miklos, D. B.; Remy, C.; Jekel, M.; Linden, K. G.; Drewes, J. E.; Hübner, U., Evaluation  
664 of advanced oxidation processes for water and wastewater treatment—a critical review. *Water*  
665 *Research* **2018**, 139, 118-131.
- 666 13. Prasse, C.; Stalter, D.; Schulte-Oehlmann, U.; Oehlmann, J.; Ternes, T. A., Spoilt for  
667 choice: a critical review on the chemical and biological assessment of current wastewater treatment  
668 technologies. *Water research* **2015**, 87, 237-270.
- 669 14. Wang, N. N.; Zheng, T.; Zhang, G. S.; Wang, P., A review on Fenton-like processes for  
670 organic wastewater treatment. *Journal of Environmental Chemical Engineering* **2016**, 4 (1), 762-  
671 787.
- 672 15. Radjenovic, J.; Sedlak, D. L., Challenges and opportunities for electrochemical processes  
673 as next-generation technologies for the treatment of contaminated water. *Environmental Science*  
674 *& Technology* **2015**, 49 (19), 11292-11302.
- 675 16. Jasper, J. T.; Yang, Y.; Hoffmann, M. R., Toxic Byproduct Formation during  
676 Electrochemical Treatment of Latrine Wastewater. *Environmental Science & Technology* **2017**,  
677 51 (12), 7111-7119.
- 678 17. Lienert, J.; B□rki, T.; Escher, I. B., Reducing micropollutants with source control:  
679 substance flow analysis of 212 pharmaceuticals in faeces and urine. *Water science and technology:*  
680 *a journal of the International Association on Water Pollution Research* **2005**, 56 (5), 87-96.
- 681 18. Lienert, J.; Gudel, K.; Escher, B. I., Screening method for ecotoxicological hazard  
682 assessment of 42 pharmaceuticals considering human metabolism and excretory routes.  
683 *Environmental Science & Technology* **2007**, 41 (12), 4471-4478.
- 684 19. Shargel, L.; Andrew, B.; Wu-Pong, S., *Applied biopharmaceutics and pharmacokinetics*.  
685 Appleton & Lange Stamford: 1999.
- 686 20. Wienkers, L. C.; Heath, T. G., Predicting in vivo drug interactions from in vitro drug  
687 discovery data. *Nature reviews Drug discovery* **2005**, 4 (10), 825.
- 688 21. Daniel, W., Metabolism of psychotropic drugs: pharmacological and clinical relevance.  
689 *Polish journal of pharmacology* **1995**, 47 (5), 367-379.
- 690 22. Buxton, G. V.; Greenstock, C. L.; Helman, W. P.; Ross, A. B., Critical review of rate  
691 constants for reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals ( $\cdot\text{OH}/\cdot\text{O}$ — in  
692 aqueous solution. *Journal of physical and chemical reference data* **1988**, 17 (2), 513-886.
- 693 23. Garcia-Ac, A.; Broséus, R.; Vincent, S.; Barbeau, B.; Prévost, M.; Sauvé, S., Oxidation  
694 kinetics of cyclophosphamide and methotrexate by ozone in drinking water. *Chemosphere* **2010**,  
695 79 (11), 1056-1063.
- 696 24. Zhang, R. C.; Yang, Y. K.; Huang, C. H.; Li, N.; Liu, H.; Zhao, L.; Sun, P. Z., UV/H<sub>2</sub>O<sub>2</sub>  
697 and UV/PDS Treatment of Trimethoprim and Sulfamethoxazole in Synthetic Human Urine:  
698 Transformation Products and Toxicity. *Environmental Science & Technology* **2016**, 50 (5), 2573-  
699 2583.



- 700 25. Cotillas, S.; Lacasa, E.; Sáez, C.; Canizares, P.; Rodrigo, M. A., Electrolytic and electro-  
701 irradiated technologies for the removal of chloramphenicol in synthetic urine with diamond  
702 anodes. *Water research* **2018**, *128*, 383-392.
- 703 26. Jojoa-Sierra, D. S.; Silva-Agredo, J.; Herrera-Calderon, E.; Torres-Palma, A. R.,  
704 Elimination of the antibiotic norfloxacin in municipal wastewater, urine and seawater by  
705 electrochemical oxidation on IrO anodes. *The Science of the total environment* **2017**, *575*, 1228-  
706 1238.
- 707 27. Cho, K.; Hoffmann, M. R., Urea Degradation by Electrochemically Generated Reactive  
708 Chlorine Species: Products and Reaction Pathways. *Environmental Science & Technology* **2014**,  
709 *48* (19), 11504-11511.
- 710 28. Urbańczyk, E.; Sowa, M.; Simka, W., Urea removal from aqueous solutions—a review.  
711 *Journal of Applied Electrochemistry* **2016**, *46* (10), 1011-1029.
- 712 29. Cotillas, S.; Lacasa, E.; Herraiz, M.; Sáez, C.; Cañizares, P.; Rodrigo, M. A., The Role of  
713 the Anode Material in Selective Penicillin G Oxidation in Urine. *ChemElectroChem* **2019**, *6* (5),  
714 1376-1384.
- 715 30. Cotillas, S.; Lacasa, E.; Sáez, C.; Cañizares, P.; Rodrigo, M. A., Removal of  
716 pharmaceuticals from the urine of polymedicated patients: A first approach. *Chemical Engineering*  
717 *Journal* **2018**, *331*, 606-614.
- 718 31. Li, H.; Yu, Q. N.; Yang, B.; Li, Z. J.; Lei, L. C., Electro-catalytic oxidation of artificial  
719 human urine by using BDD and IrO<sub>2</sub> electrodes. *Journal of Electroanalytical Chemistry* **2015**,  
720 *738*, 14-19.
- 721 32. Jasper, J. T.; Shafaat, O. S.; Hoffmann, M. R., Electrochemical Transformation of Trace  
722 Organic Contaminants in Latrine Wastewater. *Environmental Science & Technology* **2016**, *50*  
723 (18), 10198-10208.
- 724 33. Yang, Y.; Shin, J.; Jasper, T. J.; Hoffmann, R. M., Multilayer Heterojunction Anodes for  
725 Saline Wastewater Treatment: Design Strategies and Reactive Species Generation Mechanisms.  
726 *Environmental science & technology* **2016**, *50* (16), 8780-8787.
- 727 34. Zollig, H.; Remmele, A.; Morgenroth, E.; Udert, K. M., Removal rates and energy demand  
728 of the electrochemical oxidation of ammonia and organic substances in real stored urine.  
729 *Environmental Science-Water Research & Technology* **2017**, *3* (3), 480-491.
- 730 35. Zollig, H.; Remmele, A.; Fritzsche, C.; Morgenroth, E.; Udert, K. M., Formation of  
731 chlorination byproducts and their emission pathways in chlorine mediated electro-oxidation of  
732 urine on active and nonactive type anodes. *Environmental Science & Technology* **2015**, *49* (18),  
733 11062-11069.
- 734 36. Rose, C.; Parker, A.; Jefferson, B.; Cartmell, E., The characterization of feces and urine: a  
735 review of the literature to inform advanced treatment technology. *Critical reviews in*  
736 *environmental science and technology* **2015**, *45* (17), 1827-1879.
- 737 37. Udert, M. K.; Larsen, A. T.; Biebow, M.; Gujer, W., Urea hydrolysis and precipitation  
738 dynamics in a urine-collecting system. *Water research* **2003**, *37* (11), 2571-2582.
- 739 38. Udert, K. M.; Larsen, T. A.; Gujer, W., Biologically induced precipitation in urine-  
740 collecting systems. *Water Science and Technology: Water Supply* **2003**, *3* (3), 71-78.
- 741 39. Udert, K. M.; Larsen, T. A.; Gujer, W., Estimating the precipitation potential in urine-  
742 collecting systems. *Water Research* **2003**, *37* (11), 2667-2677.
- 743 40. Armstrong, D. A.; Huie, R. E.; Koppenol, W. H.; Lyman, S. V.; Merényi, G.; Neta, P.;  
744 Ruscic, B.; Stanbury, D. M.; Steenken, S.; Wardman, P., Standard electrode potentials involving

radicals in aqueous solution: inorganic radicals (IUPAC Technical Report). *Pure and Applied Chemistry* **2015**, 87 (11-12), 1139-1150.

41. Neta, P.; Maruthamuthu, P.; Carton, P.; Fessenden, R., Formation and reactivity of the amino radical. *The Journal of Physical Chemistry* **1978**, 82 (17), 1875-1878.

42. Neta, P.; Huie, R. E.; Ross, A. B., Rate constants for reactions of inorganic radicals in aqueous solution. *Journal of Physical and Chemical Reference Data* **1988**, 17 (3), 1027-1284.

43. Mazellier, P.; Leroy, É.; De Laat, J.; Legube, B., Transformation of carbendazim induced by the H<sub>2</sub>O<sub>2</sub>/UV system in the presence of hydrogenocarbonate ions: involvement of the carbonate radical. *New journal of chemistry* **2002**, 26 (12), 1784-1790.

44. Clifton, C. L.; Huie, R. E., Rate constants for some hydrogen abstraction reactions of the carbonate radical. *International journal of chemical kinetics* **1993**, 25 (3), 199-203.

45. Canonica, S.; Kohn, T.; Mac, M.; Real, F. J.; Wirz, J.; von Gunten, U., Photosensitizer method to determine rate constants for the reaction of carbonate radical with organic compounds. *Environmental science & technology* **2005**, 39 (23), 9182-9188.

46. Lei, Y.; Cheng, S.; Luo, N.; Yang, X.; An, T., Rate Constants and Mechanisms of the Reactions of Cl• and Cl<sub>2</sub>•-with Trace Organic Contaminants. *Environmental science & technology* **2019**, 53 (19), 11170-11182.

47. Xiao, S.; Qu, J.; Zhao, X.; Liu, H.; Wan, D., Electrochemical process combined with UV light irradiation for synergistic degradation of ammonia in chloride-containing solutions. *Water research* **2009**, 43 (5), 1432-1440.

48. Ji, Y.; Bai, J.; Li, J.; Luo, T.; Qiao, L.; Zeng, Q.; Zhou, B., Highly selective transformation of ammonia nitrogen to N<sub>2</sub> based on a novel solar-driven photoelectrocatalytic-chlorine radical reactions system. *Water research* **2017**, 125, 512-519.

49. Shen, Z.; Li, J.; Zhang, Y.; Bai, J.; Tan, X.; Li, X.; Qiao, L.; Xu, Q.; Zhou, B., Highly efficient total nitrogen and simultaneous total organic carbon removal for urine based on the photoelectrochemical cycle reaction of chlorine and hydroxyl radicals. *Electrochimica Acta* **2019**, 297, 1-9.

50. Long, L.; Bu, Y.; Chen, B.; Sadiq, R., Removal of urea from swimming pool water by UV/VUV: The roles of additives, mechanisms, influencing factors, and reaction products. *Water research* **2019**, 161, 89-97.

51. Hubler, D.; Baygents, J. C.; Chaplin, B.; Farrell, J., Understanding chlorite and chlorate formation associated with hypochlorite generation at boron doped diamond film anodes. *Journal of The Electrochemical Society* **2014**, 161 (12), E182-E189.

52. Buxton, G. V.; Bydder, M.; Salmon, G. A., Reactivity of chlorine atoms in aqueous solution Part 1 The equilibrium Cl<sup>-</sup> + MNSbd<sup>+</sup> ⇌ Cl-Cl<sup>-</sup> 2. *Journal of the Chemical Society, Faraday Transactions* **1998**, 94 (5), 653-657.

53. Qiang, Z.; Adams, C. D., Determination of monochloramine formation rate constants with stopped-flow spectrophotometry. *Environmental science & technology* **2004**, 38 (5), 1435-1444.

54. Blatchley III, E. R.; Cheng, M., Reaction mechanism for chlorination of urea. *Environmental science & technology* **2010**, 44 (22), 8529-8534.

55. Scialdone, O.; Guarisco, C.; Galia, A.; Herbois, R., Electroreduction of aliphatic chlorides at silver cathodes in water. *Journal of Electroanalytical Chemistry* **2010**, 641 (1-2), 14-22.

56. Sonoyama, N.; Sakata, T., Electrochemical continuous decomposition of chloroform and other volatile chlorinated hydrocarbons in water using a column type metal impregnated carbon fiber electrode. *Environmental science & technology* **1999**, 33 (19), 3438-3442.

790 57. Ma, J.; Yan, M.; Kuznetsov, A. M.; Masliy, A. N.; Ji, G.; Korshin, G. V., Rotating ring-  
791 disk electrode and quantum-chemical study of the electrochemical reduction of monoiodoacetic  
792 acid and iodoform. *Environmental science & technology* **2015**, *49* (22), 13542-13549.

793 58. Su, X.; Bromberg, L.; Tan, K.-J.; Jamison, T. F.; Padhye, L. P.; Hatton, T. A.,  
794 Electrochemically mediated reduction of Nitrosamines by Hemin-Functionalized Redox  
795 electrodes. *Environmental Science & Technology Letters* **2017**, *4* (4), 161-167.

796 59. Brown, G. M., The reduction of chlorate and perchlorate ions at an active titanium  
797 electrode. *Journal of electroanalytical chemistry and interfacial electrochemistry* **1986**, *198* (2),  
798 319-330.

799 60. Wang, D.; Huang, C.; Chen, J.; Lin, H.; Shah, S., Reduction of perchlorate in dilute  
800 aqueous solutions over monometallic nano-catalysts: Exemplified by tin. *Separation and*  
801 *Purification Technology* **2007**, *58* (1).

802 61. Wang, D.; Shah, S. I.; Chen, J.; Huang, C., Catalytic reduction of perchlorate by H<sub>2</sub> gas in  
803 dilute aqueous solutions. *Separation and Purification Technology* **2008**, *60* (1), 14-21.

804 62. Yang, Q.; Yao, F.; Zhong, Y.; Wang, D.; Chen, F.; Sun, J.; Hua, S.; Li, S.; Li, X.; Zeng,  
805 G., Catalytic and electrocatalytic reduction of perchlorate in water ? A review. *Chemical*  
806 *Engineering Journal* **2016**, *306*.

807 63. Haynes, W. M., *CRC handbook of chemistry and physics*. CRC press: 2014.

808 64. BACTRIM (sulfamethoxazole and trimethoprim) injection, for intravenous use.  
809 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/018374s0251bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s0251bl.pdf).

810 65. FDA, U. S. CYCLOPHOSPHAMIDE injection, for intravenous use.  
811 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/012141s090\\_012142s1121bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090_012142s1121bl.pdf).

812 66. FDA BACTRIM™ sulfamethoxazole and trimethoprim DS (double strength) tablets and  
813 tablets USP. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2010/017377s0671bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017377s0671bl.pdf).

814 67. Joqueviel, C.; Martino, R.; Gilard, V.; Malet-Martino, M.; Canal, P.; Niemeyer, U., Urinary  
815 excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic  
816 resonance spectroscopy. *Drug metabolism and Disposition* **1998**, *26* (5), 418-428.

817 68. Yalkowsky, H.; Press, Y. H. C., *Handbook of Aqueous Solubility Data*. By Samuel. 2003.

818 69. Larsen, T. A.; Udert, K. M.; Lienert, J., *Source separation and decentralization for*  
819 *wastewater management*. Iwa Publishing: 2013.

820 70. Putnam, D. F., *Composition and concentrative properties of human urine*. **1971**.

821 71. Kapałka, A.; Baltruschat, H.; Comninellis, C., Electrochemical Oxidation of Organic  
822 Compounds Induced by Electro - Generated Free Hydroxyl Radicals on BDD Electrodes.  
823 *Synthetic Diamond Films: Preparation, Electrochemistry, Characterization, and Applications*  
824 **2011**, 237-260.

825 72. Comninellis, C., Electrocatalysis in the electrochemical conversion/combustion of organic  
826 pollutants for waste water treatment. *Electrochimica Acta* **1994**, *39* (11-12), 1857-1862.

827 73. Halász, G.; Gyüre, B.; Jánosi, I. M.; Szabó, K. G.; Tél, T., Vortex flow generated by a  
828 magnetic stirrer. *American Journal of Physics* **2007**, *75* (12), 1092-1098.

829 74. Prentice, G., *Electrochemical engineering principles*. Prentice Hall: 1991.

830 75. Dodd, M. C.; Huang, C.-H., Transformation of the antibacterial agent sulfamethoxazole in  
831 reactions with chlorine: kinetics, mechanisms, and pathways. *Environmental science & technology*  
832 **2004**, *38* (21), 5607-5615.

833 76. Donaghue, A.; Chaplin, B. P., Effect of select organic compounds on perchlorate formation  
834 at boron-doped diamond film anodes. *Environmental science & technology* **2013**, *47* (21), 12391-  
835 12399.

- 836 77. Clarke, K.; Edge, R.; Johnson, V.; Land, E.; Navaratnam, S.; Truscott, T., The carbonate  
837 radical: its reactivity with oxygen, ammonia, amino acids, and melanins. *The Journal of Physical*  
838 *Chemistry A* **2008**, *112* (41), 10147-10151.
- 839 78. Hora, P. I.; Novak, P. J.; Arnold, W. A., Photodegradation of pharmaceutical compounds  
840 in partially nitrated wastewater during UV irradiation. *Environmental Science: Water Research*  
841 *& Technology* **2019**, *5* (5), 897-909.
- 842 79. Scholes, R. C.; Prasse, C.; Sedlak, D. L., The Role of Reactive Nitrogen Species in  
843 Sensitized Photolysis of Wastewater-Derived Trace Organic Contaminants. *Environmental*  
844 *science & technology* **2019**.
- 845 80. Organization, W. H., Guidelines for Drinking-Water Quality: Incorporating the First  
846 Addendum. Geneva, Switzerland. *World Health Organization* **2017**.
- 847 81. Jung, Y. J.; Baek, K. W.; Oh, B. S.; Kang, J.-W., An investigation of the formation of  
848 chlorate and perchlorate during electrolysis using Pt/Ti electrodes: The effects of pH and reactive  
849 oxygen species and the results of kinetic studies. *Water research* **2010**, *44* (18), 5345-5355.
- 850 82. Azizi, O.; Hubler, D.; Schrader, G.; Farrell, J.; Chaplin, B. P., Mechanism of perchlorate  
851 formation on boron-doped diamond film anodes. *Environmental science & technology* **2011**, *45*  
852 (24), 10582-10590.
- 853 83. Pagsberg, P. B., Investigation of the NH<sub>2</sub> radical produced by pulse radiolysis of ammonia  
854 in aqueous solution. *Aspects of Research at Risø* **1972**, *5*, 209.
- 855 84. Draganić, Z. D.; Negron-Mendoza, A.; Sehested, K.; Vujošević, S. I.; Navarro-Gonzales,  
856 R.; Albarran-Sanchez, M.; Draganić, I. G., Radiolysis of aqueous solutions of ammonium  
857 bicarbonate over a large dose range. *International Journal of Radiation Applications and*  
858 *Instrumentation. Part C. Radiation Physics and Chemistry* **1991**, *38* (3), 317-321.
- 859 85. Chaplin, B. P., Critical review of electrochemical advanced oxidation processes for water  
860 treatment applications. *Environmental Science: Processes & Impacts* **2014**, *16* (6), 1182-1203.
- 861 86. Watts, M. J.; Linden, K. G., Chlorine photolysis and subsequent OH radical production  
862 during UV treatment of chlorinated water. *Water Research* **2007**, *41* (13), 2871-2878.
- 863 87. Nowell, L. H.; Hoigné, J., Photolysis of aqueous chlorine at sunlight and ultraviolet  
864 wavelengths—II. Hydroxyl radical production. *Water Research* **1992**, *26* (5), 599-605.
- 865 88. Fang, J.; Fu, Y.; Shang, C., The roles of reactive species in micropollutant degradation in  
866 the UV/free chlorine system. *Environmental science & technology* **2014**, *48* (3), 1859-1868.
- 867 89. Remucal, C.; Manley, D., Emerging investigators series: the efficacy of chlorine photolysis  
868 as an advanced oxidation process for drinking water treatment. *Environmental Science: Water*  
869 *Research & Technology* **2016**, *2* (4), 565-579.
- 870 90. Alfassi, Z.; Mosseri, S.; Neta, P., Reactivities of chlorine atoms and peroxy radicals  
871 formed in the radiolysis of dichloromethane. *The Journal of Physical Chemistry* **1989**, *93* (4),  
872 1380-1385.
- 873 91. O'Neill, P.; Steenken, S.; Schulte-Frohlinde, D., Formation of radical cations of  
874 methoxylated benzenes by reaction with OH radicals, Ti<sup>2+</sup>, Ag<sup>2+</sup>, and SO<sub>4</sub><sup>•-</sup> in aqueous solution.  
875 An optical and conductometric pulse radiolysis and in situ radiolysis electron spin resonance study.  
876 *Journal of Physical Chemistry* **1975**, *79* (25), 2773-2779.
- 877 92. Hess, E. Boron-doped Diamond Sensors for the Determination of Organic Compounds in  
878 Aqueous Media. University of the Western Cape, 2010.
- 879 93. Montilla, F.; Michaud, P.; Morallon, E.; Vazquez, J.; Cominellis, C., Electrochemical  
880 oxidation of benzoic acid at boron-doped diamond electrodes. *Electrochimica Acta* **2002**, *47* (21),  
881 3509-3513.

- 882 94. Weinberg, N.; Marr, D.; Wu, C., Sensitive probe for double layer structure. Potential  
883 dependent competitive cyanation and methoxylation of 1, 4-dimethoxybenzene. *Journal of the*  
884 *American Chemical Society* **1975**, *97* (6), 1499-1504.
- 885 95. de Martinez, M. C.; Marquez, O.; Marquez, J.; Hahn, F.; Beden, B.; Crouigneau, P.;  
886 Rakotondrainibe, A.; Lamy, C., In situ spectroscopic investigation of the anodic oxidation of 1, 4-  
887 dimethoxybenzene at platinum electrodes. *Synthetic metals* **1997**, *88* (3), 187-196.
- 888 96. Jing, Y.; Chaplin, B. P., Mechanistic study of the validity of using hydroxyl radical probes  
889 to characterize electrochemical advanced oxidation processes. *Environmental science &*  
890 *technology* **2017**, *51* (4), 2355-2365.

891